Atara BiotherapeuticsATRA +1.38%31 Current Ratio is 2.16 as of Mar. 2026, which is 60% below its 10-year median of 5.40. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,416 Biotechnology companies, Atara Biotherapeutics ranks worse than 66.38% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Atara Biotherapeutics's current ratio for the quarter that ended in Mar. 2026 was 2.16.
Atara Biotherapeutics has a current ratio of 2.16. It generally indicates good short-term financial strength.
The historical rank and industry rank for Atara Biotherapeutics's Current Ratio or its related term are showing as below:
ATRA'
s Current Ratio Range Over the Past 10 Years
Min: 0.42 Med: 5.4 Max: 30.15
Current: 2.16
During the past 13 years, Atara Biotherapeutics's highest Current Ratio was 30.15. The lowest was 0.42. And the median was 5.40.
ATRA's Current Ratio is ranked worse than 66.38% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs ATRA: 2.16
Atara Biotherapeutics (NAS:ATRA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Atara Biotherapeutics Current Ratio Related Terms
Atara Biotherapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRA vs RNTX, IBIO, OSTX: Current Ratio Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atara Biotherapeutics (ATRA) has a Current Ratio of 2.16 as of Mar. 2026. This is 60% below median its historical median of 5.40. Over the past decade, Atara Biotherapeutics' Current Ratio has ranged from 0.42 to 30.15. According to the industry distribution chart, Atara Biotherapeutics ranks #940 out of 1416 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Atara Biotherapeutics' Current Ratio too high?
Atara Biotherapeutics' current Current Ratio of 2.16 is 60% below median its 10-year median of 5.40. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 30.15. The Biotechnology industry median Current Ratio is 3.89. Atara Biotherapeutics' value of 2.16 is 44.4% below this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #940 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Current Ratio compare to RNTX and IBIO?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #940 out of 1416 companies for Current Ratio. This places Atara Biotherapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Atara Biotherapeutics' value of 2.16 is 44.4% below this benchmark. Historically, Atara Biotherapeutics' own Current Ratio has ranged from 0.42 to 30.15 over the past decade. While the company's 10-year median is 5.40 vs. the industry median of 3.89, Atara Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Current Ratio of 2.16 is 44.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Current Ratio is 2.16, which is 60% below median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.28 — trading 559% above its estimated fair value. The current Current Ratio is 2.16, which is 60% below median its 10-year median of 5.40 and 44.4% below the Biotechnology industry median of 3.89. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Current Ratio is 2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $10.28 is trading 559% above its estimated GF Value™ of $1.56.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
Current Ratio: 2.16 (60% below median its 10-year median of 5.40)
GF Value™: $1.56 vs. price of $10.28 (559% above fair value)
Industry Position: 44.4% below the Biotechnology median (#940 of 1416)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score
Get the complete analysis for ATRA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
